|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
February 2015
|
|
gptkbp:ATCCode
|
L01EF01
|
|
gptkbp:brand
|
gptkb:palbociclib
|
|
gptkbp:CASNumber
|
gptkb:571190-30-2
|
|
gptkbp:chemicalFormula
|
C24H29N7O2
|
|
gptkbp:combines
|
gptkb:fulvestrant
gptkb:letrozole
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:drugClass
|
CDK4/6 inhibitor
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:form
|
100 mg
75 mg
125 mg
|
|
gptkbp:halfLife
|
29 hours
|
|
gptkbp:indication
|
HER2-negative breast cancer
hormone receptor-positive breast cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
inhibits cyclin-dependent kinases 4 and 6
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2027
|
|
gptkbp:pregnancyCategory
|
D
|
|
gptkbp:prescriptionRequired
|
yes
https://labeling.pfizer.com/ShowLabeling.aspx?id=2191
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
alopecia
infections
neutropenia
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:palbociclib
gptkb:Pfizer_Ibrance_royalties
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ibrance
|